The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
Source abstract
Abstract
Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDCA), has permeation-enhancing effects. Sodium alginate (SA) was used to microencapsulate G and CDCA to produce control (G-SA) and test (G-CDCA-SA) microcapsules. Both microcapsules showed uniform structure, morphology, and good stability profiles. CDCA reduced G-release at pH 7.8, while G-release was negligible at lower pH values in both microcapsules. CDCA incorporation resulted in less swelling and stronger microcapsules, suggesting improved stability.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Drug Transport and Resistance Mechanisms · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Biotechnology and Drug Development Research Laboratory, School of Pharmacy, Curtin Health Innovation Research Institute, Biosciences Research Precinct, School of Pharmacy, Curtin University, Perth WA, Australia
Faculty of Science and Engineering, Curtin University, Perth WA, Australia
Curtin Health Innovation Research Institute, Biosciences Research Precinct, School of Biomedical Sciences, Curtin University, Perth WA, Australia
References (45)
Show source-provided references
1. Acartürk F, · J Microencapsulation · 1998 · 16 · 291
2. 10.1016/j.ijpharm.2007.03.04710.1016/j.ijpharm.2007.03.047 ↗
3. 10.1007/BF0319102610.1007/BF03191026 ↗
4. 10.1007/BF0319138310.1007/BF03191383 ↗
5. Al-Salami H · Pharmacol Rep · 2008 · 60 · 532
6. 10.1358/mf.2008.30.2.115965210.1358/mf.2008.30.2.1159652 ↗
7. 10.1358/mf.2008.30.2.115965210.1358/mf.2008.30.2.1159652 ↗
8. Al-Salami H · ArchDrug Inf · 2008 · 1 · 35
9. Al-Salami H · Drug Metabol Rev · 2008 · 40 · 81
10. 10.1111/j.2042-7158.2010.01214.x10.1111/j.2042-7158.2010.01214.x ↗
11. 10.3109/03639045.2012.68138310.3109/03639045.2012.681383 ↗
12. 10.1016/S0939-6411(03)00160-710.1016/S0939-6411(03)00160-7 ↗
13. 10.4314/tjpr.v8i5.4808510.4314/tjpr.v8i5.48085 ↗
14. 10.1016/j.ijpharm.2005.04.03710.1016/j.ijpharm.2005.04.037 ↗
15. Campbellt D · Diab Res Clin Prac · 1991 · 14 · 26
16. 10.1205/cherd.0508810.1205/cherd.05088 ↗
17. 10.1007/s00011005065610.1007/s000110050656 ↗
18. Gill P · J Biomol Tech · 2010 · 21 · 167
19. 10.1016/j.pharep.2014.12.01810.1016/j.pharep.2014.12.018 ↗
20. 10.1038/sj.emboj.760104910.1038/sj.emboj.7601049 ↗
21. 10.1194/jlr.R900007-JLR20010.1194/jlr.R900007-JLR200 ↗
22. 10.1016/j.bbamem.2006.02.01110.1016/j.bbamem.2006.02.011 ↗
23. 10.1205/fbp.0439910.1205/fbp.04399 ↗
24. 10.1007/BF0319071010.1007/BF03190710 ↗
25. 10.1007/BF0319111010.1007/BF03191110 ↗
26. 10.1007/BF0319071410.1007/BF03190714 ↗
27. Mooranian A · Drug Des Devel Ther · 2014 · 8 · 1221
28. Mooranian A · Artif Cells Nanomed Biotechnol · 2014 · 1
29. Mooranian A · Drug Des Devel Ther · 2014 · 8 · 1673
30. Nayak BS · Int J Pharm Sci · 2009 · 1 · 112
31. 10.2306/scienceasia1513-1874.2010.36.31910.2306/scienceasia1513-1874.2010.36.319 ↗
32. 10.3109/21691401.2015.102484510.3109/21691401.2015.1024845 ↗
33. 10.1208/s12249-008-9041-010.1208/s12249-008-9041-0 ↗
34. 10.1016/j.ijbiomac.2012.12.03310.1016/j.ijbiomac.2012.12.033 ↗
35. 10.1016/j.ejps.2005.01.01610.1016/j.ejps.2005.01.016 ↗
36. 10.1016/j.addr.2013.07.01010.1016/j.addr.2013.07.010 ↗
37. 10.1016/j.carbpol.2006.02.00810.1016/j.carbpol.2006.02.008 ↗
38. 10.1016/S0032-3861(96)00458-210.1016/S0032-3861(96)00458-2 ↗
39. 10.3109/10837450.2010.50289810.3109/10837450.2010.502898 ↗
40. Tormo MA · Diabete Metab · 1989 · 15 · 170
41. 10.1002/jps.2109310.1002/jps.21093 ↗
42. 10.1016/S0928-4931(00)00177-610.1016/S0928-4931(00)00177-6 ↗
43. 10.1016/S0168-3659(02)00237-710.1016/S0168-3659(02)00237-7 ↗
44. 10.1021/mp200201y10.1021/mp200201y ↗
45. 10.1211/jpp.61.08.000910.1211/jpp.61.08.0009 ↗